Search Results - "Norio Akuta"

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020 by Tokushige, Katsutoshi, Ikejima, Kenichi, Ono, Masafumi, Eguchi, Yuichiro, Kamada, Yoshihiro, Itoh, Yoshito, Akuta, Norio, Yoneda, Masato, Iwasa, Motoh, Yoneda, Masashi, Otsuka, Motoyuki, Tamaki, Nobuharu, Kogiso, Tomomi, Miwa, Hiroto, Chayama, Kazuaki, Enomoto, Nobuyuki, Shimosegawa, Tooru, Takehara, Tetsuo, Koike, Kazuhiko

“…Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only in Western countries but also in Japan. Within the wide spectrum of…”
Get full text

Prognostic Impact of Surgical Intervention After Lenvatinib Treatment for Advanced Hepatocellular Carcinoma by Shindoh, Junichi, Kawamura, Yusuke, Kobayashi, Yuta, Kobayashi, Masahiro, Akuta, Norio, Okubo, Satoshi, Suzuki, Yoshiyuki, Hashimoto, Masaji

“…Background With the introduction of new molecular-targeted agents, an increasing number of patients with advanced hepatocellular carcinoma (HCC) are benefiting…”
Get full text

Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020 by Tokushige, Katsutoshi, Ikejima, Kenichi, Ono, Masafumi, Eguchi, Yuichiro, Kamada, Yoshihiro, Itoh, Yoshito, Akuta, Norio, Yoneda, Masato, Iwasa, Motoh, Yoneda, Masashi, Otsuka, Motoyuki, Tamaki, Nobuharu, Kogiso, Tomomi, Miwa, Hiroto, Chayama, Kazuaki, Enomoto, Nobuyuki, Shimosegawa, Tooru, Takehara, Tetsuo, Koike, Kazuhiko

“…Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only in Western countries but also in Japan. Within the wide spectrum of…”
Get full text

Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non‐alcoholic fatty liver disease complicated by diabetes mellitus by Akuta, Norio, Kawamura, Yusuke, Watanabe, Chizuru, Nishimura, Akihiro, Okubo, Minoru, Mori, Yasumichi, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Saitoh, Satoshi, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, Ikeda, Kenji, Kumada, Hiromitsu

“…Aim The aim of this study was to investigate the therapeutic potential of sodium glucose cotransporter 2 inhibitor (SGLT2I) as an effective therapeutic option…”
Get full text

Time-to-Interventional Failure as a New Surrogate Measure for Survival Outcomes after Resection of Hepatocellular Carcinoma by Shindoh, Junichi, Kawamura, Yusuke, Kobayashi, Yuta, Akuta, Norio, Kobayashi, Masahiro, Suzuki, Yoshiyuki, Ikeda, Kenji, Hashimoto, Masaji

“…Purpose This study sought to investigate the clinical impact of repeated interventions for recurrent hepatocellular carcinoma (HCC) and to establish a new…”
Get full text

SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology by Akuta, Norio, Kawamura, Yusuke, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Saitoh, Satoshi, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, Ikeda, Kenji, Kumada, Hiromitsu

“…Objective The aim of this study was to determine the long-term effects of a sodium-glucose cotransporter 2 inhibitor (SGLT2i) in nonalcoholic fatty liver…”
Get full text

Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma by Ikeda, Kenji, Kawamura, Yusuke, Kobayashi, Masahiro, Kominami, Yoko, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Akuta, Norio, Saitoh, Satoshi, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, Kumada, Hiromitsu

“…Background Suppressive activity of recurrence by interferon-free direct-acting antivirals (DAA) is not elucidated after curative treatment of hepatocellular…”
Get full text

The useful predictors of zinc deficiency for the management of chronic liver disease by Iritani, Soichi, Kawamura, Yusuke, Muraishi, Nozomu, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Akuta, Norio, Kobayashi, Masahiro, Saitoh, Satoshi, Suzuki, Fumitaka, Arase, Yasuji, Ikeda, Kenji, Suzuki, Yoshiyuki, Kumada, Hiromitsu

“…Background Zinc deficiency is likely to occur in chronic liver disease. The aim of this study was to determine the prevalence of zinc deficiency in different…”
Get full text

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients by Ono, Atsushi, Suzuki, Fumitaka, Kawamura, Yusuke, Sezaki, Hitomi, Hosaka, Tetsuya, Akuta, Norio, Kobayashi, Masahiro, Suzuki, Yoshiyuki, Saitou, Satoshi, Arase, Yasuji, Ikeda, Kenji, Kobayashi, Mariko, Watahiki, Sachiyo, Mineta, Rie, Kumada, Hiromitsu

“…Background & Aims We determined the antiviral potency and viral resistance rate after 4 years of continuous entecavir treatment in patients with chronic…”
Get full text

Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs by Yamashige, Daiki, Hosaka, Tetsuya, Suzuki, Fumitaka, Fujiyama, Shunichiro, Kawamura, Yusuke, Sezaki, Hitomi, Akuta, Norio, Kobayashi, Masahiro, Suzuki, Yoshiyuki, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, Kobayashi, Mariko, Kumada, Hiromitsu

“…Background Few studies have demonstrated the potency of tenofovir alafenamide (TAF) in patients with poor response to other nucleos(t)ide analogs (NAs)…”
Get full text

Serial changes in liver stiffness and controlled attenuation parameter following direct‐acting antiviral therapy against hepatitis C virus genotype 1b by Ogasawara, Nobuhiko, Kobayashi, Masahiro, Akuta, Norio, Kominami, Yoko, Fujiyama, Shunichiro, Kawamura, Yusuke, Sezaki, Hitomi, Hosaka, Tetsuya, Suzuki, Fumitaka, Saitoh, Satoshi, Suzuki, Yoshiyuki, Arase, Yasuji, Ikeda, Kenji, Kobayashi, Mariko, Kumada, Hiromitsu

“…Little information is available on the impact of direct‐acting antiviral (DAA) therapy on changes in liver fibrosis and steatosis. Liver stiffness (LS) and…”
Get full text

Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study by Hosaka, Tetsuya, Suzuki, Fumitaka, Kobayashi, Masahiro, Seko, Yuya, Kawamura, Yusuke, Sezaki, Hitomi, Akuta, Norio, Suzuki, Yoshiyuki, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, Kobayashi, Mariko, Kumada, Hiromitsu

“…Background Clearance of hepatitis B surface antigen (HBsAg) is considered the ultimate goal in chronic hepatitis B treatment. One treatment option is long-term…”
Get full text

Treatment efficacy of diet and exercise program for fatty liver and pretreatment predictors by Akuta, Norio, Kawamura, Yusuke, Fujiyama, Shunichiro, Nakamichi, Kenichi, Saegusa, Eiji, Ogura, Hidetoshi, Kato, Masaki, Doi, Etsuko, Inoue, Naoko, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Mariko, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, Suzuki, Yoshiyuki, Kumada, Hiromitsu, Suzuki, Fumitaka

“…Aims Both diet and exercise counseling are recommended for patients with fatty liver, including nonalcoholic fatty liver disease (NAFLD), to achieve weight…”
Get full text

Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib by Kasuya, Kayoko, Kawamura, Yusuke, Kobayashi, Masahiro, Shindoh, Junichi, Kobayashi, Yuta, Kajiwara, Akira, Iritani, Soichi, Fujiyama, Shunichiro, Hosaka, Tetsuya, Saitoh, Satoshi, Sezaki, Hitomi, Akuta, Norio, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Ikeda, Kenji, Arase, Yasuji, Eguchi, Yuichiro, Hashimoto, Masaji, Kumada, Hiromitsu

“…Objective A survival benefit was demonstrated for ramucirumab (RAM) in patients with unresectable hepatocellular carcinoma (uHCC) and α-fetoprotein (AFP)…”
Get full text

ASO Visual Abstract: Prognostic Impact of Surgical Intervention After Lenvatinib Treatment for Advanced Hepatocellular Carcinoma by Shindoh, Junichi, Kawamura, Yusuke, Kobayashi, Yuta, Kobayashi, Masahiro, Akuta, Norio, Okubo, Satoshi, Suzuki, Yoshiyuki, Hashimoto, Masaji

Get full text

Advantage of liver stiffness measurement before and after direct‐acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C by Ogasawara, Nobuhiko, Saitoh, Satoshi, Akuta, Norio, Sezaki, Hitomi, Suzuki, Fumitaka, Fujiyama, Shunichiro, Kawamura, Yusuke, Hosaka, Tetsuya, Kobayashi, Masahiro, Suzuki, Yoshiyuki, Arase, Yasuji, Ikeda, Kenji, Kumada, Hiromitsu

“…Aim The risk of development of hepatocellular carcinoma (HCC) persisted in patients with advanced fibrosis, even after achieving sustained virologic response…”
Get full text

Potential of ultra‐highly sensitive immunoassays for hepatitis B surface and core‐related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance by Suzuki, Fumitaka, Hosaka, Tetsuya, Imaizumi, Masayasu, Kobayashi, Mariko, Ohue, Chiharu, Suzuki, Yoshiyuki, Fujiyama, Shunichiro, Kawamura, Yusuke, Sezaki, Hitomi, Akuta, Norio, Kobayashi, Masahiro, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, Kumada, Hiromitsu

“…Aims Hepatitis B surface antigen (HBsAg) seroclearance indicates a “functional cure” in chronic hepatitis B (CHB) virus infection. However, several cases of…”
Get full text

PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication by Miki, Daiki, Akita, Tomoyuki, Kurisu, Akemi, Kawaoka, Tomokazu, Nakajima, Tomoaki, Hige, Shuhei, Karino, Yoshiyasu, Toyoda, Hidenori, Kumada, Takashi, Tsuge, Masataka, Hiramatsu, Akira, Imamura, Michio, Aikata, Hiroshi, Hayes, Clair Nelson, Honda, Koichi, Seike, Masataka, Akuta, Norio, Kobayashi, Mariko, Kumada, Hiromitsu, Tanaka, Junko, Chayama, Kazuaki

“…Background Even though both interferon (IFN)-based and direct-acting antiviral (DAA) therapies against hepatitis C virus (HCV) reduce the risk of…”
Get full text

Thrombotic Microangiopathy, Podocytopathy, and Damage to the Renal Tubules with Severe Proteinuria and Acute Renal Dysfunction Induced by Lenvatinib by Nakashima, Saki, Sekine, Akinari, Sawa, Naoki, Kawamura, Yusuke, Kono, Kei, Kinowaki, Keiichi, Kawada, Masahiro, Hasegawa, Eiko, Akuta, Norio, Suzuki, Yoshiyuki, Ohashi, Kenichi, Takaichi, Kenmei, Ubara, Yoshifumi, Hoshino, Junichi

“…Lenvatinib, a tyrosine kinase inhibitor (TKI), is a stronger inhibitor of vascular endothelial growth factor receptor, fibroblast growth factor receptors 1 to…”
Get full text

Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan by Akuta, Norio, Sezaki, Hitomi, Suzuki, Fumitaka, Fujiyama, Shunichiro, Kawamura, Yusuke, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Saitoh, Satoshi, Suzuki, Yoshiyuki, Arase, Yasuji, Ikeda, Kenji, Kumada, Hiromitsu

“…Predictors of treatment efficacy with ledipasvir plus sofosbuvir as direct‐acting antiviral (DAA) regimen for HCV infection are still unclear. Retreatment…”
Get full text